Lumos Pharma — FY2023 Earnings Presentation
10 slides from Lumos Pharma's earnings presentation, Mar 7, 2024
Slide 1: Full Year 2023 Financial Results & Clinical Update
1 Full Year 2023 Financial Results & Clinical Update March 7, 2024
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward- looking statements within the meaning of The Private Securities Litigation Reform
Slide 3: Agenda
3 Agenda • Lisa Miller, Vice President of Investor Relations • Rick Hawkins, Chief Executive Officer & Chairman • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • Lori Lawley, Chief Financial Officer • Duke Pitukcheewanont, MD, Chief Medical
Slide 4: Management – Significant Clinical Development and Commercial Experience
4 Management – Significant Clinical Development and Commercial Experience Richard Hawkins Chairman & CEO Developed Growth Hormone (GH) Receptor Antagonist for Acromegaly at Sensus (sold to Pfizer). Built one of the first contract recombinant protein manufacturing facilities (Covance Biotechnology).
Slide 5: OraGrowtH Trials – Topline Phase 2 Data Highlights
5 OraGrowtH Trials – Topline Phase 2 Data Highlights o Met all primary and secondary endpoints o PEM test was reproducible and predicted response to LUM-201 o LUM-201 restored GH secretion through increased amplitude of pulsatility and normalized IGF-1 o LUM-201 promoted growth similar to injectable
Slide 6: LUM-201 Data Suggests Greater Durability of Response than rhGH to 24 Months
6 LUM-201 Data Suggests Greater Durability of Response than rhGH to 24 Months OraGrowtH210 & OraGrowtH212 Combined (1.6 and 3.2 mg/kg LUM-201) • Preliminary data demonstrate LUM-201 AHV durable to 24 months • More moderate year 2 AHV decline than rhGH likely due to LUM-201 restoration of GH and IGF-
Slide 7: LUM-201 Normalizes GH Secretion in Moderate PGHD
7 Normal healthy (IC-GH‡) Untreated PGHD (IC-GH‡) LUM-201 (Baseline GH)* LUM-201 (Treated 6M GH)* Comparator arm rhGH 34 µg/kg/day Zadik† N = 22 Albertsson- Wikland†† 5.0 + 1.3 1.4 + 0.5 1.7 + 1.3¥ 3.3 + 1.8 to 4.0 + 2.1¥ ~20 ‡ IC-GH: integrated concentration of Growth Hormone; data represent mean +
Slide 8: Next Steps – Upcoming Milestones
8 Next Steps o Full 12-month data from OraGrowtH210 Trial to be announced in 2Q 2024 o Additional 24-month data to be reported o End-of-Phase 2 meeting with FDA in 2Q 2024 o Supportive comprehensive data package o Initiation of pivotal Phase 3 program anticipated in 4Q 2024 o Multi-national trial de
Slide 9: Lumos Pharma Financial Information as of December 31, 2023
9 Lumos Pharma Financial Information as of December 31, 2023 Values in USD LUMO Cash, cash equivalents, & short-term investments to support operations through 3Q 2024, inclusive of activities related to advancing the PGHD program into Phase 3 Year 2023 Year 2022 R&D Expense $22.1M $17.9M G&A Expense
Slide 10: Investment Thesis
10 Investment Thesis Lead asset targeting children with growth disorders Attractive Market Opportunity Novel Asset with Unique MOA • Daily oral expected to be well received in GH markets • Market research supports rapid conversation to oral and potential expansion opportunities* • Novel MOA takes ad